Why do lnps go to the liver

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Lipid nanoparticles (LNPs) primarily accumulate in the liver due to their size and surface properties, which facilitate uptake by liver-resident cells like hepatocytes and Kupffer cells. This hepatic targeting is crucial for delivering mRNA vaccines, such as those for COVID-19, where over 90% of LNPs from Moderna and Pfizer-BioNTech vaccines localize to the liver post-injection. The liver's rich blood supply and fenestrated endothelium allow efficient LNP entry, making it a key site for therapeutic gene editing and protein production applications.

Key Facts

LNPs typically range from 50-200 nm in size, optimizing liver accumulation via the enhanced permeability and retention effect
Approximately 70-90% of intravenously administered LNPs are cleared by the liver within hours of injection
The first FDA-approved LNP drug was Onpattro (patisiran) in 2018 for treating hereditary transthyretin-mediated amyloidosis
COVID-19 mRNA vaccines using LNPs showed >90% efficacy in clinical trials in 2020-2021
Liver-targeting LNPs can achieve up to 40% protein expression efficiency in hepatocytes for gene therapies

Overview

Lipid nanoparticles (LNPs) are advanced drug delivery systems that have revolutionized medicine, particularly through their role in mRNA vaccine delivery during the COVID-19 pandemic. Historically, lipid-based delivery systems date back to the 1960s with liposome development, but modern LNPs emerged in the 1990s with improved stability and targeting capabilities. The breakthrough came with the 2018 FDA approval of Onpattro, the first LNP-based therapeutic for rare disease treatment. LNPs consist of four main components: ionizable lipids, phospholipids, cholesterol, and PEG-lipids, formulated to protect fragile cargo like mRNA or siRNA. Their development accelerated dramatically during 2020-2021, with global LNP production scaling from laboratory quantities to billions of doses for COVID-19 vaccines. Pharmaceutical companies invested over $10 billion in LNP technology development between 2015-2022, recognizing their potential beyond vaccines for cancer therapies, genetic disorders, and personalized medicine applications.

How It Works

LNPs accumulate in the liver through multiple physiological mechanisms. Their optimal size (50-200 nm) allows passage through the liver's fenestrated sinusoidal endothelium, which has pores of 100-200 nm. Once in the space of Disse, LNPs interact with hepatocytes via apolipoprotein E (ApoE) adsorption, which binds to LDL receptors on liver cells. The ionizable lipids in LNPs become positively charged in acidic endosomes, facilitating endosomal escape and cargo release into the cytoplasm. Kupffer cells (liver macrophages) also phagocytose some LNPs, particularly those with certain surface modifications. This hepatic targeting is enhanced by the liver's dual blood supply (portal vein and hepatic artery) and high blood flow (1.5 L/min, representing 25% of cardiac output). Recent studies show that PEGylation density on LNP surfaces significantly affects liver accumulation, with optimal PEG coverage reducing non-specific uptake while maintaining hepatocyte targeting efficiency.

Why It Matters

Liver targeting by LNPs has transformed treatment possibilities for numerous diseases. For mRNA vaccines, hepatic production of viral proteins stimulates robust immune responses, contributing to the >90% efficacy of COVID-19 vaccines. In gene therapy, liver-specific LNP delivery enables treatment of genetic disorders like hemophilia, where factor VIII or IX production in hepatocytes can restore clotting function. Clinical trials show LNP-delivered gene editing tools (like CRISPR-Cas9) achieve 20-40% editing efficiency in liver cells for conditions such as hereditary transthyretin amyloidosis. Beyond therapeutics, liver-accumulating LNPs facilitate research into liver biology and disease models. The economic impact is substantial, with the global LNP market projected to reach $12.5 billion by 2028, driven by ongoing development of liver-targeted treatments for metabolic diseases, cancers, and infectious diseases.